Neumora Therapeutics (NMRA) Competitors $1.71 -0.09 (-5.00%) Closing price 10/22/2025 04:00 PM EasternExtended Trading$1.72 +0.02 (+0.88%) As of 10/22/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NMRA vs. TRVI, IMNM, WVE, CVAC, MAZE, ATAI, CALT, ARDX, SYRE, and PHVSShould you be buying Neumora Therapeutics stock or one of its competitors? The main competitors of Neumora Therapeutics include Trevi Therapeutics (TRVI), Immunome (IMNM), WAVE Life Sciences (WVE), CureVac (CVAC), Maze Therapeutics (MAZE), atai Life Sciences (ATAI), Calliditas Therapeutics AB (publ) (CALT), Ardelyx (ARDX), Spyre Therapeutics (SYRE), and Pharvaris (PHVS). These companies are all part of the "pharmaceutical products" industry. Neumora Therapeutics vs. Its Competitors Trevi Therapeutics Immunome WAVE Life Sciences CureVac Maze Therapeutics atai Life Sciences Calliditas Therapeutics AB (publ) Ardelyx Spyre Therapeutics Pharvaris Neumora Therapeutics (NASDAQ:NMRA) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership. Which has preferable valuation and earnings, NMRA or TRVI? Trevi Therapeutics is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeumora TherapeuticsN/AN/A-$243.79M-$1.57-1.09Trevi TherapeuticsN/AN/A-$47.91M-$0.42-25.93 Which has more volatility and risk, NMRA or TRVI? Neumora Therapeutics has a beta of 2.92, indicating that its share price is 192% more volatile than the S&P 500. Comparatively, Trevi Therapeutics has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Is NMRA or TRVI more profitable? Trevi Therapeutics' return on equity of -41.44% beat Neumora Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neumora TherapeuticsN/A -98.95% -87.68% Trevi Therapeutics N/A -41.44%-38.21% Do insiders & institutionals hold more shares of NMRA or TRVI? 47.7% of Neumora Therapeutics shares are owned by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are owned by institutional investors. 26.8% of Neumora Therapeutics shares are owned by insiders. Comparatively, 18.3% of Trevi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media prefer NMRA or TRVI? In the previous week, Neumora Therapeutics' average media sentiment score of 0.00 equaled Trevi Therapeutics'average media sentiment score. Company Overall Sentiment Neumora Therapeutics Neutral Trevi Therapeutics Neutral Do analysts prefer NMRA or TRVI? Neumora Therapeutics currently has a consensus target price of $7.14, indicating a potential upside of 317.71%. Trevi Therapeutics has a consensus target price of $21.75, indicating a potential upside of 99.72%. Given Neumora Therapeutics' higher possible upside, research analysts plainly believe Neumora Therapeutics is more favorable than Trevi Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neumora Therapeutics 3 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.00Trevi Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89 SummaryTrevi Therapeutics beats Neumora Therapeutics on 8 of the 12 factors compared between the two stocks. Get Neumora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NMRA vs. The Competition Export to ExcelMetricNeumora TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$291.50M$3.47B$6.17B$10.67BDividend YieldN/A2.24%5.72%4.86%P/E Ratio-1.0922.9129.0927.13Price / SalesN/A463.56584.28126.20Price / CashN/A45.5937.1261.42Price / Book0.9610.2912.246.43Net Income-$243.79M-$52.53M$3.33B$276.63M7 Day Performance-3.93%-0.60%-0.79%-0.77%1 Month Performance-10.47%10.30%5.27%0.68%1 Year Performance-87.15%13.51%69.02%32.03% Neumora Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NMRANeumora Therapeutics1.9537 of 5 stars$1.71-5.0%$7.14+317.7%-87.8%$291.50MN/A-1.09108TRVITrevi Therapeutics1.96 of 5 stars$9.71-2.8%$21.75+124.0%+237.2%$1.22BN/A-23.1220IMNMImmunome1.7766 of 5 stars$14.25+2.4%$23.20+62.8%+35.8%$1.21B$9.04M-4.6340News CoverageWVEWAVE Life Sciences4.6779 of 5 stars$7.79+2.5%$20.33+161.0%-51.6%$1.21B$108.30M-8.66240Analyst ForecastCVACCureVac3.5174 of 5 stars$5.39+0.2%$6.83+26.8%+96.0%$1.21B$579.18M5.61880MAZEMaze Therapeutics2.4968 of 5 stars$28.57+4.2%$33.83+18.4%N/A$1.20B$167.50M0.00121Short Interest ↑ATAIatai Life Sciences3.5621 of 5 stars$5.40+5.9%$11.40+111.1%+340.6%$1.19B$310K-7.8380Analyst ForecastGap UpCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ARDXArdelyx4.1688 of 5 stars$5.01+1.4%$11.70+133.5%-10.9%$1.19B$333.61M-21.7890Upcoming EarningsSYRESpyre Therapeutics3.0213 of 5 stars$18.92-1.1%$54.29+186.9%-35.0%$1.16B$890K-5.5673PHVSPharvaris2.6758 of 5 stars$22.07+0.4%$32.60+47.7%+4.9%$1.15BN/A-6.5730 Related Companies and Tools Related Companies Trevi Therapeutics Competitors Immunome Competitors WAVE Life Sciences Competitors CureVac Competitors Maze Therapeutics Competitors atai Life Sciences Competitors Calliditas Therapeutics AB (publ) Competitors Ardelyx Competitors Spyre Therapeutics Competitors Pharvaris Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NMRA) was last updated on 10/23/2025 by MarketBeat.com Staff From Our PartnersRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NMRA Stock Alerts